title: Adverse events of monoclonal antibodies used for cancer therapy.
abstract: In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients. Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has continued to expand, currently encompassing a stunning amount of 20 distinct molecules for 11 targets. We provide a brief scientific background on the use of MoAbs in cancer therapy, review all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular adverse events, and pulmonary adverse events), and discuss the mechanism and treatment of adverse events.
authors.affiliation: Department of Oncology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Guan
authors.affiliation: Department of Oncology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Yan-Ping
authors.initials: YP
authors.lastname: Zhou
authors.affiliation: Department of Allergy, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Jin-Lu
authors.initials: JL
authors.lastname: Sun
authors.affiliation: Department of Oncology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
authors.forename: Shu-Chang
authors.initials: SC
authors.lastname: Chen
mesh_terms: D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D000069283:Rituximab / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000912:Antibodies, Neoplasm; D000069283:Rituximab